leisure time -WSS

leisure time

author：hotspot 2025-09-30 14:08:40 - browse：317

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： ReNAgade cuts staff seven months after raising $300 million

WSS

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

U.K. Biobank has 500,000 peoples' genome sequences available

Venture capital firm's plans to take over Akron hospital face hurdles

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

With clinical trial data readouts, here's how to spot spin

Reconstructing family trees of blood cells may help predict disease

focus

leisure time

focus

Peter Hotez and the public health issue of online harassment

With clinical trial data readouts, here's how to spot spin

Sports medicine is finally prioritizing gender equality

FDA investigates CAR

Trump demands the U.S. pay no more for drugs than other countries … again

What don’t we know about an Alzheimer’s drug side effect?

Bright Health sells Medicare Advantage business to Molina

Vertex non

Duchenne breakthrough therapy leaves behind pioneering families

With clinical trial data readouts, here's how to spot spin

hotspot

Pediatric cancer treatments threatened by a new FDA policy

Medicare Advantage insurers face 0.2% cut to 2025 payments

Bernie Sanders is gearing up to subpoena pharma CEOs

Syphilis numbers in the United States reach record heights

Rep. Raul Ruiz on the physician shortage and more

Medicare drug price negotiation legal challenge met with skepticism

entertainment

Wikipedia

leisure time

leisure time